# EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

> **NCT04664179** · PHASE1 · RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 52 (estimated)

## Conditions studied

- EBV-Related Hodgkin Lymphoma
- EBV-Related Lymphoproliferative Disorder
- EBV Related Non-Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** Dose Level 1A: 2 x 10^7 cells/m2
- **BIOLOGICAL:** Dose Level 2A: 6 x 10^7 cells/m2
- **BIOLOGICAL:** Dose Level 2B: 6 x 10^7 cells/m2
- **BIOLOGICAL:** Dose Level 3B: 2 x 10^8 cells/m2
- **BIOLOGICAL:** Dose Level 3A: 2 x 10^8 cells/m2

## Key facts

- **NCT ID:** NCT04664179
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-31
- **Primary completion:** 2026-04-01
- **Final completion:** 2039-03-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-12-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04664179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04664179, "EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04664179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*